Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
| ▸ | IL1B | P01584 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31253537 | 0.95 | KCNH2 (0.37) | KCNH2IDH2KDM1AMAOB | |
| SCHEMBL31014264 | 0.77 | KCNH2 (0.40) | KCNH2KDM1AMAOB | |
| SCHEMBL25145686 | 0.75 | DPP7 (0.39) | KCNH2 | |
| SCHEMBL31014267 | 0.73 | KCNH2 (0.44) | KCNH2KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL2477180 | 0.71 | KCNH2 (0.41) | KCNH2IDH2IL1BKDM1AMAOB | |
| SCHEMBL31014214 | 0.71 | KCNH2 (0.38) | KCNH2KDM1AMAOB | |
| SCHEMBL30674942 | 0.68 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL3403980 | 0.66 | — | — | |
| SCHEMBL16834527 | 0.66 | — | — | |
| SCHEMBL19042986 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | claimed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | claimed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | KCNH2 3247/4885IDH2 2211/4885IL1B 4219/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | KCNH2 3247/4885IDH2 2211/4885IL1B 4219/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | KCNH2 3247/4885IDH2 2211/4885IL1B 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.